{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:44:14Z","timestamp":1793385854914,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32260014"],"award-info":[{"award-number":["32260014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bcp.2026.118344","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T06:18:12Z","timestamp":1786429092000},"page":"118344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["NAMPT beyond NAD+ biosynthesis: roles in tumor microenvironment remodeling and cancer progression"],"prefix":"10.1016","volume":"253","author":[{"given":"Wei-Dong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Zhou","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Juan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Yan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9221-0387","authenticated-orcid":false,"given":"Jiang-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118344_b0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","article-title":"Tumor microenvironment and therapeutic response","volume":"387","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118344_b0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41568-023-00660-9","article-title":"Beyond genetics: driving cancer with the tumour microenvironment behind the wheel","volume":"24","author":"Yuan","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2026.118344_b0015","article-title":"Novel carbamate-based o-aminobenzamide derivatives as potent antigastric carcinoma agents via disrupting NAD+ salvage synthesis","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0020","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001250","article-title":"Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice","volume":"8","author":"Selvanesan","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118344_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2024.05.013","article-title":"Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer","author":"Jiang","year":"2024","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118344_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113208","article-title":"Nicotinamide N-methyltransferase (NNMT): a key enzyme in cancer metabolism and therapeutic target","volume":"142","author":"Sun","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2026.118344_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2015.02.004","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer","volume":"151","author":"Sampath","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2026.118344_b0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.semcdb.2019.05.001","article-title":"Targeting metabolic reprogramming in metastatic melanoma: the key role of nicotinamide phosphoribosyltransferase (NAMPT)","volume":"98","author":"Audrito","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0045","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-019-1150-2","article-title":"NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling","volume":"569","author":"Chowdhry","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118344_b0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.metabol.2018.01.001","article-title":"The role of extracellular and intracellular nicotinamide phosphoribosyl-transferase in cancer: diagnostic and therapeutic perspectives and challenges","volume":"82","author":"Dalamaga","year":"2018","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bcp.2026.118344_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cmet.2020.10.021","article-title":"NAD+ metabolism maintains inducible PD-L1 expression to drive tumor immune evasion","volume":"33","author":"Lv","year":"2021","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118344_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106189","article-title":"NAMPT: a critical driver and therapeutic target for cancer","volume":"145","author":"Gasparrini","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0065","article-title":"NAMPT-driven M2 polarization of tumor-associated macrophages leads to an immunosuppressive microenvironment in colorectal cancer","volume":"11","author":"Hong","year":"2024","journal-title":"Adv. Sci. (Weinh. Baden-Wurtt. Ger.)"},{"key":"10.1016\/j.bcp.2026.118344_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117595","article-title":"Drug discovery targeting nicotinamide phosphoribosyltransferase (NAMPT): Updated progress and perspectives","volume":"99","author":"Wen","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cmet.2016.07.005","article-title":"Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle","volume":"24","author":"Frederick","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.bcp.2026.118344_b0080","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","article-title":"NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential","volume":"5","author":"Xie","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.bcp.2026.118344_b0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism","volume":"11","author":"Garten","year":"2015","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118344_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1268756","article-title":"Extracellular nicotinamide phosphoribosyltransferase: role in disease pathophysiology and as a biomarker","volume":"14","author":"Semerena","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2026.118344_b0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nsmb1114","article-title":"Structure of Nampt\/PBEF\/visfatin, a mammalian NAD+ biosynthetic enzyme","volume":"13","author":"Wang","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0100","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nsmb1105","article-title":"Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents","volume":"13","author":"Khan","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jmb.2006.06.082","article-title":"Crystal structure of visfatin\/pre-B cell colony-enhancing factor 1\/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866","volume":"362","author":"Kim","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0110","doi-asserted-by":"crossref","first-page":"13748","DOI":"10.1073\/pnas.0903898106","article-title":"A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT","volume":"106","author":"Burgos","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bcp.2026.118344_b0115","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1021\/ja310180c","article-title":"Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase","volume":"135","author":"Burgos","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bcp.2026.118344_b0120","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3389\/fonc.2018.00622","article-title":"NAD metabolism in cancer therapeutics","volume":"8","author":"Yaku","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118344_b0125","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1158\/0008-5472.CAN-20-1094","article-title":"Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118344_b0130","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ijc.31808","article-title":"NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils","volume":"144","author":"Pylaeva","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118344_b0135","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/cvr\/cvm111","article-title":"Visfatin induces human endothelial VEGF and MMP-2\/9 production via MAPK and PI3K\/akt signalling pathways: novel insights into visfatin-induced angiogenesis","volume":"78","author":"Adya","year":"2008","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.bcp.2026.118344_b0140","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbamcr.2009.09.006","article-title":"Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis","volume":"1793","author":"Kim","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2026.118344_b0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/metabo6040033","article-title":"The redox status of cancer cells supports mechanisms behind the Warburg effect","volume":"6","author":"Moreira","year":"2016","journal-title":"Metabolites"},{"key":"10.1016\/j.bcp.2026.118344_b0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41392-020-00354-w","article-title":"NAD+ metabolism, stemness, the immune response, and cancer","volume":"6","author":"Navas","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118344_b0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: how does it benefit cancer cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci"},{"key":"10.1016\/j.bcp.2026.118344_b0160","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood-2014-07-589069","article-title":"Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia","volume":"125","author":"Audrito","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118344_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110294","article-title":"NAMPT inhibition reduces macrophage inflammation through the NAD+\/PARP1 pathway to attenuate liver ischemia\u2013reperfusion injury","volume":"369","author":"Lu","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bcp.2026.118344_b0170","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1158\/0008-5472.CAN-18-1544","article-title":"Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells","volume":"79","author":"Travelli","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118344_b0175","doi-asserted-by":"crossref","first-page":"25758","DOI":"10.1074\/jbc.M112.362343","article-title":"NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0180","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.apsb.2021.12.017","article-title":"NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bcp.2026.118344_b0185","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1038\/s41467-021-22923-5","article-title":"A Stat1 bound enhancer promotes nampt expression and function within tumor associated macrophages","volume":"12","author":"Huffaker","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118344_b0190","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.bbamcr.2008.01.004","article-title":"Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells","volume":"1783","author":"Kim","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"2007","key":"10.1016\/j.bcp.2026.118344_b0195","first-page":"1748","article-title":"Visfatin, an adipocytokine with proinflammatory and immunomodulating properties","volume":"178","author":"Moschen","year":"1950","journal-title":"J. Immunol. (baltim. Md"},{"key":"10.1016\/j.bcp.2026.118344_b0200","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118344_b0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau0135","article-title":"T cell stemness and dysfunction in tumors are triggered by a common mechanism","author":"Vodnala","year":"2019","journal-title":"Science 363"},{"key":"10.1016\/j.bcp.2026.118344_b0210","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/1078-0432.CCR-17-2575","article-title":"NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP","volume":"24","author":"Lucena-Cacace","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118344_b0215","doi-asserted-by":"crossref","first-page":"E8247","DOI":"10.1073\/pnas.1610921114","article-title":"An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma","volume":"113","author":"Gujar","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2026.118344_b0220","doi-asserted-by":"crossref","first-page":"99514","DOI":"10.18632\/oncotarget.20577","article-title":"NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis","volume":"8","author":"Lucena-Cacace","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2026.118344_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx198","article-title":"Nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic target in BRAF-mutated metastatic melanoma","volume":"110","author":"Audrito","year":"2018","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2026.118344_b0230","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fonc.2019.01514","article-title":"Beyond energy metabolism: exploiting the additional roles of NAMPT for cancer therapy","volume":"9","author":"Heske","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2026.118344_b0235","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/acs.biochem.2c00655","article-title":"Mechanism of allosteric modulation of nicotinamide phosphoribosyltransferase to elevate cellular NAD+","volume":"62","author":"Ratia","year":"2023","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2026.118344_b0240","doi-asserted-by":"crossref","first-page":"16704","DOI":"10.1021\/acs.jmedchem.3c01406","article-title":"Synthesis, optimization, and structure-activity relationships of nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulators (N-PAMs)","volume":"66","author":"Shen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0245","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1021\/acs.jmedchem.3c02112","article-title":"Channeling nicotinamide phosphoribosyltransferase (NAMPT) to address life and death","volume":"67","author":"Velma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0250","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1021\/jm400186h","article-title":"Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (nampt) inhibitors","volume":"56","author":"Zheng","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0255","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1021\/jm4008664","article-title":"Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors","volume":"56","author":"Zheng","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0260","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1021\/acs.jmedchem.6b00324","article-title":"Structure-based design of potent nicotinamide phosphoribosyltransferase inhibitors with promising in vitro and in vivo antitumor activities","volume":"59","author":"Bai","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0265","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1535-7163.MCT-16-0819","article-title":"Discovery and characterization of novel nonsubstrate and substrate NAMPT inhibitors","volume":"16","author":"Wilsbacher","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118344_b0270","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.7150\/thno.85356","article-title":"Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy","volume":"13","author":"Kim","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118344_b0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/1471-2407-10-677","article-title":"Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase","volume":"10","author":"Olesen","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2026.118344_b0280","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbrc.2017.07.143","article-title":"Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation","volume":"491","author":"Guo","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2026.118344_b0285","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2016.0401","article-title":"Efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma: a phase 2 clinical trial","volume":"152","author":"Goldinger","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.bcp.2026.118344_b0290","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118344_b0295","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor","volume":"26","author":"Holen","year":"2008","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2026.118344_b0300","first-page":"2843","article-title":"A phase I study of CHS 828 in patients with solid tumor malignancy","volume":"8","author":"Hovstadius","year":"2002","journal-title":"Clin. Cancer Res.: off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.bcp.2026.118344_b0305","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ejca.2004.12.023","article-title":"Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: an ECSG\/EORTC study","volume":"41","author":"Ravaud","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2026.118344_b0310","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1128\/MCB.00112-09","article-title":"The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors","volume":"29","author":"Watson","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0315","unstructured":"Oncotartis, Inc., A phase 1 study of OT-82 in patients with relapsed or refractory lymphoma, clinicaltrials.gov, 2020. https:\/\/clinicaltrials.gov\/study\/NCT03921879 (accessed July 23, 2026)."},{"key":"10.1016\/j.bcp.2026.118344_b0320","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-019-0692-5","article-title":"OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis","volume":"34","author":"Korotchkina","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2026.118344_b0325","first-page":"187","article-title":"First-in-human phase I study of KPT-9274, a first-in-class dual inhibitor of PAK4 and NAMPT, in patients with advanced solid malignancies, Targeted","volume":"21","author":"Razak","year":"2026","journal-title":"Oncol"},{"key":"10.1016\/j.bcp.2026.118344_b0330","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","article-title":"Dual and specific inhibition of NAMPT and PAK4 by KPT-9274 decreases kidney cancer growth","volume":"15","author":"Abu Aboud","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118344_b0335","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13402-018-0385-5","article-title":"Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation","volume":"41","author":"Kraus","year":"2018","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bcp.2026.118344_b0340","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1021\/cb500347p","article-title":"NAMPT is the cellular target of STF-31-like small-molecule probes","volume":"9","author":"Adams","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0345","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12192-019-01063-2","article-title":"\u03b1-mangostin reduced the viability of A594 cells in vitro by provoking ROS production through downregulation of NAMPT\/NAD","volume":"25","author":"Ding","year":"2020","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.bcp.2026.118344_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103059","article-title":"Role of secreted extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in prostate cancer progression: novel biomarker and therapeutic target","volume":"61","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.118344_b0355","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.3390\/ph14121322","article-title":"A humanized monoclonal antibody targeting extracellular nicotinamide phosphoribosyltransferase prevents aggressive prostate cancer progression","volume":"14","author":"Sun","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2026.118344_b0360","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007010","article-title":"Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer","volume":"11","author":"Travelli","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118344_b0365","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s10456-024-09956-2","article-title":"Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) drives abnormal pericyte-rich vasculature in triple-negative breast cancer","volume":"28","author":"Moro","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bcp.2026.118344_b0370","article-title":"Safety, tolerability and pharmacokinetics of the eNAMPT-neutralizing ALT-100 mab in healthy volunteers","volume":"3","author":"Miele","year":"2024","journal-title":"J. Clin. Res. Clin. Trials"},{"key":"10.1016\/j.bcp.2026.118344_b0375","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1021\/acs.jmedchem.4c00193","article-title":"Design of FK866-based degraders for blocking the nonenzymatic functions of nicotinamide phosphoribosyltransferase","volume":"67","author":"Lu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0380","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1021\/acs.jmedchem.5c01827","article-title":"Development of PROTACs targeting the moonlighting enzyme nicotinamide phosphoribosyltransferase (NAMPT) for breast cancer therapy","volume":"69","author":"Galli","year":"2026","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2026.118344_b0385","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1089\/dna.2022.0214","article-title":"MicroRNA-26b reduces cell viability by inhibition of nicotinamide phosphoribosyltransferase in breast cancer cells","volume":"41","author":"Ameli Mojarad","year":"2022","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.bcp.2026.118344_b0390","article-title":"Nicotinamide phosphoribosyl transferase (nampt) is a target of microRNA-26b in colorectal cancer cells","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2026.118344_b0395","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.3390\/ijms23105787","article-title":"Different Effects of RNAi-mediated downregulation or chemical inhibition of NAMPT in an isogenic IDH mutant and wild-type glioma cell model","volume":"23","author":"Clausing","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118344_b0400","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2478\/enr-2020-0005","article-title":"Silencing of NAMPT leads to up-regulation of insulin receptor substrate 1 gene expression in U87 glioma cells","volume":"54","author":"Tsymbal","year":"2020","journal-title":"Endocr. Regul."},{"key":"10.1016\/j.bcp.2026.118344_b0405","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1535-7163.MCT-20-1105","article-title":"PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus","volume":"20","author":"Mpilla","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118344_b0410","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00432-022-04124-9","article-title":"Targeting NAD metabolism regulates extracellular adenosine levels to improve the cytotoxicity of CD8+ effector T cells in the tumor microenvironment of gastric cancer","volume":"149","author":"Liu","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118344_b0415","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1158\/1535-7163.MCT-23-0632","article-title":"NAD+ metabolic enzyme inhibitor as radiosensitizer for malignant meningioma and its modulation of P53 expression","volume":"23","author":"Lv","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118344_b0420","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1111\/bph.13505","article-title":"Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine","volume":"173","author":"Grolla","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118344_b0425","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s44321-024-00051-z","article-title":"The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor","volume":"16","author":"Yang","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2026.118344_b0430","article-title":"Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)\/pre-B cell colony (PBEF)\/visfatin linking obesity and inflammation in humans","volume":"54","author":"F. D, N. M, K. J, E. S, D. K, G. A, P.-Q. S, B. S, R. T, S. M, B. M, K. W, K. A","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2026.118344_b0435","doi-asserted-by":"crossref","first-page":"H415","DOI":"10.1152\/ajpheart.00468.2012","article-title":"Nampt secreted from cardiomyocytes promotes development of cardiac hypertrophy and adverse ventricular remodeling","volume":"304","author":"Pillai","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2026.118344_b0440","article-title":"Enzymology of extracellular NAD metabolism","volume":"78","author":"Massimiliano","year":"2021","journal-title":"Cell. Mol. Life Sci. : CMLS"},{"key":"10.1016\/j.bcp.2026.118344_b0445","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/ph15070848","article-title":"Identification of NAPRT inhibitors with anti-cancer properties by In silico drug discovery","volume":"15","author":"Ghanem","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bcp.2026.118344_b0450","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/emmm.201201250","article-title":"Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells","volume":"4","author":"Bajrami","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bcp.2026.118344_b0455","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00318.2009","article-title":"Skeletal muscle NAMPT is induced by exercise in humans","volume":"298","author":"Costford","year":"2010","journal-title":"Am. J. Physiol.-Endocrinol. Metabol."},{"key":"10.1016\/j.bcp.2026.118344_b0460","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14139","article-title":"Aerobic and resistance exercise training reverses age\u2010dependent decline in NAD+ salvage capacity in human skeletal muscle","volume":"7","author":"De Guia","year":"2019","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.bcp.2026.118344_b0465","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13647","article-title":"Exercise increases the release of NAMPT in extracellular vesicles and alters NAD+ activity in recipient cells","volume":"21","author":"Chong","year":"2022","journal-title":"Aging Cell"},{"key":"10.1016\/j.bcp.2026.118344_b0470","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2022.05.006","article-title":"Exercise-induced engagement of the IL-15\/IL-15R\u03b1 axis promotes anti-tumor immunity in pancreatic cancer","volume":"40","author":"Kurz","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2026.118344_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.jshs.2025.101041","article-title":"Exercise-induced extracellular vesicles delay tumor development by igniting inflammation in an immunologically cold triple-negative breast cancer mouse model","volume":"14","author":"Mlynska","year":"2025","journal-title":"J. Sport Health Sci."},{"key":"10.1016\/j.bcp.2026.118344_b0480","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-026-03053-1","article-title":"Home-based high-intensity exercise training during neoadjuvant chemotherapy is associated with favorable chemotherapy outcomes and tumor microenvironment remodeling in breast cancer","author":"Skorinkina","year":"2026","journal-title":"Cell Commun. Signal."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226006830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:15:44Z","timestamp":1788812144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226006830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":96,"alternative-id":["S0006295226006830"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118344","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAMPT beyond NAD+ biosynthesis: roles in tumor microenvironment remodeling and cancer progression","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118344"}}